Clinical Trials

Other hematologic neoplasm

40 enrolled

Leukemia, Monocytic, Acute, Leukemia, Myeloid, Acute

NCT07468136 2026-04-13

Retifanlimab With or Without Difluoromethylornithine for the Treatment of Progressive High Grade Gliomas

Phase 1/2 Not yet recruiting

33 enrolled

CNSLymphoid

Astrocytoma, Glioblastoma, Glioma, Lymphoma, Follicular, Oligodendroglioma

NCT06816979 2026-04-08

Lumbar Punctures for the Detection of ctDNA in the Cerebrospinal Fluid of Patients With Stage III and IV Non-Small Cell Lung Cancer

Phase NA Not yet recruiting

40 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

NCT07133997 2026-04-07

Recombinant Erwinia Asparaginase and Venetoclax in Combination With Blinatumomab for the Treatment of Relapsed or Refractory CD19 Positive B-cell Acute Lymphoblastic Leukemia

26 enrolled

Phase 1/2 Not yet recruiting

Burkitt Lymphoma

NCT06500481 2026-04-03

Testing Proton Craniospinal Radiation Therapy Versus the Usual Radiation Therapy for Leptomeningeal Metastasis, RADIATE-LM Trial

Phase 3 Recruiting

115 enrolled

BreastCNSThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Meningeal Carcinomatosis

NCT07225985 2026-04-03

Pralatrexate With Bendamustine and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Relapsed or Refractory T-Cell Non-Hodgkin Lymphoma

50 enrolled

Lymphoma, T-Cell

NCT03025256 2026-04-02

Intravenous and Intrathecal Nivolumab in Treating Patients With Leptomeningeal Disease

75 enrolled

DermatologicThoracic

Uveal Melanoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Melanoma, Meningeal Neoplasms, Nevus

NCT05746325 2026-04-02

Tumor Treating Fields for the Treatment of Leptomeningeal Metastases of the Spine in Patients With Breast or Lung Cancer

Phase NA Recruiting

5 enrolled

BreastCNSThoracic

Breast Neoplasms, Lung Neoplasms, Meningeal Carcinomatosis

NCT06871410 2026-03-24

Genetically Engineered Cells (CD83 CAR T Cells) for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia

Other hematologic neoplasm

26 enrolled

Leukemia, Myeloid, Acute

NCT05359211 2026-03-20

NKTR-255 in Combination With CAR-T Cell Therapy for the Treatment of Relapsed or Refractory Large B-cell Lymphoma

Phase 1 Active not recruiting

27 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT05286684 2026-03-18

Exo-LCR

Phase NA Completed

7 enrolled

BreastCNS

Breast Neoplasms, Meningeal Carcinomatosis

NCT06918431 2026-03-17

Asparaginase Erwinia Chrysanthemi With Chemotherapy for the Treatment of High-Risk Adults With Newly Diagnosed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

LymphoidOther hematologic neoplasm

53 enrolled

Burkitt Lymphoma, Precursor Cell Lymphoblastic Leukemia-Lymphoma

NCT05453500 2026-03-13

Chemotherapy (DA-EPOCH+/-R) and Targeted Therapy (Tafasitamab) for the Treatment of Newly-Diagnosed Philadelphia Chromosome Negative B Acute Lymphoblastic Leukemia

30 enrolled

Burkitt Lymphoma

NCT06784726 2026-03-13

Odronextamab for Relapsed and Refractory Large B-cell Lymphomas Before CAR-T

27 enrolled

Lymphoma, Large B-Cell, Diffuse

NCT06322602 2026-03-03

Ommaya Reservoir Placement at the Time of Biopsy for Longitudinal Biomarker Collection in Patients With Brain Tumors

Phase NA Recruiting

20 enrolled

CNS

Brain Neoplasms

NCT04872790 2026-02-10

Venetoclax, Dasatinib, Prednisone, Rituximab and Blinatumomab for the Treatment of Newly Diagnosed or Relapsed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia or Mixed Phenotype Acute Leukemia

LymphoidOther hematologic neoplasm

20 enrolled

Burkitt Lymphoma, Leukemia, Biphenotypic, Acute

NCT07398170 2026-02-09

BIOLIMEN-1

Phase NA Not yet recruiting

15 enrolled

CNS

Meningioma, Neoplastic Cells, Circulating, Neoplasm Recurrence, Local

NCT05130840 2026-01-30

Monitoring for Cancer Spread to the Central Nervous System (CNS) in People With Breast Cancer

Phase NA Active not recruiting

9 enrolled

Breast

Breast Neoplasms

NCT06895473 2026-01-30

Intrathecal Cytarabine, Methotrexate, and Hydrocortisone for the Prevention of High-Grade Chimeric Antigen Receptor T-Cell-Associated Neurotoxicity Syndrome